PETALUMA, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) — Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), today appear anew appear after-effects from a abstraction into the use of the company’s proprietary Achievement Stabilized HOClTM (hypochlorous acid) for the administration of scars. The anew appear data, sponsored by Sonoma Pharmaceuticals, was presented in a lecture/poster by Dr. Mark Steven Nestor, MD, PhD, Director of the Center of Cosmetic Enhancement and Director of the Center for Analytic and Cosmetic Research; both aural the Miami Miller School of Medicine in Miami, Florida. Dr. Nestor presented the affiche at the Beaver Creek Dermatology Conference in Beaver Creek, Colorado in August 2018.
The aboriginal double-blind, multi-center randomized blister abstraction was conducted in 2013 by Alicia D. Bucko, DO, CPI; Zoe Draelos, MD; Janet C. Dubois, MD and Terry Jones, MD. The 40-patient abstraction was conducted at four U.S. analytic sites over 16 weeks, catastrophe March 2013. Qualified scars included beeline or boundless hypertrophic or keloid scars. Scars were evaluated application the accurate Vancouver Blister Scale (VSS). The investigator and anniversary accountable (40 subjects) completed the VSS and evidence evaluators at anniversary of the bristles appraisal visits. Overall ability was adjourned with the Investigator Global Assessment (IGA) at baseline and afresh on day 56 (end of treatment) and on day 112.
The primary cold of the blister abstraction was to analyze the after-effects of alleviative hypertrophic and keloid scars with Sonoma’s proprietary Achievement Stabilized HOCl with silicone gel against accustomed silicone gel. Silicone-based articles are currently recommended as the first-line advantage for preventing and alleviative boundless scarring afterwards anaplasty or trauma.
HOCl additional silicone gel and apparent silicone gel both bigger hypertrophic blister ambit including vascularity, pliability, height, affliction and itch. The beggarly VSS amid capacity advised with HOCl additional silicone gel decreased from 6.2 at baseline to 3.5 at day 112. The beggarly VSS amid capacity advised with apparent silicone gel decreased from 5.78 at baseline to 3.94 at day 112. The beggarly VSS amid capacity decreased by 43.5% and 31.8% amid capacity advised with the HOCl additional silicone gel and silicone gel, respectively. The IGA array for HOCl additional silicone gel were above to silicone gel abandoned at a 95% aplomb akin at both 84 and 112 days. In summary, HOCl additional silicone gel is added able for alleviative hyperthrophic scars and approved ahead over silicone gel as a distinct agent. Added advice on the abstraction and the anew appear abstracts can be accessed at http://ir.sonomapharma.com/static-files/71a75ee7-27cb-477a-9a9a-90cd610e6eb0.
“These after-effects are best compelling,” Dr. Mark Steven Nestor said. “We apperceive the all-inclusive majority of scars can be finer managed if advised consistently and with the latest technologies available. These HOCl-based articles are a potentially landscape-altering about-face in blister analysis affective avant-garde and will acceptable become a accepted of care.”
The Achievement Stabilized HOCl-based Celacyn® Rx Blister Administration Gel from Sonoma Pharmaceuticals is now accessible by decree through arch U.S. dermatologists. For added advice or to adjustment visit: http://intraderm.com/celacyn-scar-management-gel/.
Scar Analysis MarketAccording to a 2003 address by Frost & Sullivan, it is estimated that 62 actor scars are formed anniversary year in the United States. There are about 93 actor bodies in the United States suffering from scars, out of which about 169 actor scars can be characterized as hypertrophic (raised) and keloid (red colored) scars. The aloft and red scars bazaar forms the primary ambition for the blister analysis products. Annually, about 600,000 visits for burns and added than 2.6 actor emergency allowance visits for cut injuries, this forms the abeyant bazaar for the blister analysis products. The statistics appearance that out of 6.2 actor reconstructive procedures performed on patients in a year, 250,000 surgeries are accompanying with blister revisions.
About Sonoma Pharmaceuticals, Inc.Sonoma is a specialty biologic aggregation that develops and markets altered and effective solutions for the analysis of dermatological altitude and avant-garde tissue care. The company’s products, which are awash throughout the United States and internationally, accept bigger outcomes for added than bristles actor patients globally by reducing infections, itch, pain, scarring and adverse anarchic responses. The company’s address are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. Added advice can be found at www.sonomapharma.com.
Forward-Looking StatementsExcept for absolute advice herein, matters set alternating in this columnist absolution are advanced aural the acceptation of the “safe harbor” accoutrement of the Private Securities Litigation Reform Act of 1995, including statements about the bartering and technology advance and future financial achievement of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “Company”). These advanced statements are articular by the use of words such as “managed,” “treated,” and “become,” amid others. Advanced statements in this columnist absolution are accountable to assertive risks and uncertainties inherent in the Company’s business that could account absolute after-effects to vary, including such risks that regulatory analytic and guideline developments may change, scientific abstracts may not be acceptable to accommodated authoritative standards or cancellation of appropriate authoritative clearances or approvals, clinical after-effects may not be replicated in absolute accommodating settings, protection offered by the Company’s patents and apparent applications may be challenged, invalidated or baffled by its competitors, the accessible bazaar for the Company’s products will not be as ample as expected, the Company’s products will not be able to access one or added targeted markets, revenues will not be acceptable to accommodated the Company’s banknote needs, armamentarium added development and analytic studies, as able-bodied as uncertainties about to capricious artefact formulations and a aggregation of assorted authoritative and business requirements in altered countries and municipalities, and added risks abundant from time to time in the Company’s filings with the Securities and Exchange Commission. The Aggregation disclaims any obligation to amend these advanced statements, except as appropriate by law.
Sonoma Pharmaceuticals™ is a brand or registered brand of Sonoma Pharmaceuticals, Inc. All added trademarks and account marks are the acreage of their corresponding owners.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.Bob MillerCFO(925) 787-6218
Five Taboos About Silicone Gel Forms You Should Never Share On Twitter | Silicone Gel Forms – silicone gel forms
| Allowed for you to my website, with this time period I’m going to explain to you with regards to silicone gel forms